2025-2034 Late Stage Chronic Kidney Disease Drugs Market Evolution: Disruptions, Innovations, and Untapped Opportunities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Late Stage Chronic Kidney Disease Drugs Market Through 2025?
The market size for drugs used in the advanced stages of chronic kidney disease has experienced swift expansion in the last few years. The market, which stands at $7.08 billion in 2024, is projected to rise to $7.92 billion in 2025, signifying a compound annual growth rate (CAGR) of 11.9%. The upward trend during the historic period is due to enhanced diagnostic techniques, an aging population, a surge in diabetes and hypertension cases, heightened awareness of kidney conditions, and growth in pharmaceutical R&D.

What's the Projected Size of the Global Late Stage Chronic Kidney Disease Drugs Market by 2029?
Expectations are high for the upcoming surge in the late stage chronic kidney disease drugs market as forecasts suggest a considerable expansion up to $12.2 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.4%. The anticipated progression during the forecast period is due to factors such as an increase in healthcare spending, use of precision medicine methodologies, an amplified focus on regenerative medicine, an emphasis on patient-directed care, and worldwide endeavors for kidney disease awareness. Principal trends to note during the forecast period include the broadening scope of regenerative medicine therapies, an advancement in telemedicine services for CKD management, the creation of combination therapies, a focus on preemptive intervention strategies, and a mounting interest in biomarker-based diagnostics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Top Growth Drivers in the Late Stage Chronic Kidney Disease Drugs Industry: What's Accelerating the Market?
The rise in chronic kidney ailments is anticipated to fuel the expansion of the market for drugs aimed at late-stage chronic kidney disease. Chronic kidney diseases encompass a wide spectrum of disorders that impede kidney structure and function. Drugs for late-stage chronic kidney diseases help manage blood pressure in patients, reduce protein loss, and halt further kidney damage. They are also used to manage symptoms and prevent complications. For example, the Centers for Disease Control and Prevention (CDC), a health agency based in the U.S., reported in May 2024 that an estimated 14% of U.S. adults, roughly 35.5 million individuals, are thought to be suffering from chronic kidney diseases. Consequently, the growing prevalence of chronic kidney disease is fuelling the growth of the market for drugs tackling late-stage chronic kidney disease.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp

What Trends Will Shape the Late Stage Chronic Kidney Disease Drugs Market Through 2029 and Beyond?
Product innovation is increasingly becoming a dominant trend in the late-stage chronic kidney disease drug market. To maintain their market position, major firms in this market are focusing on the development of novel drug products. An example of this trend can be seen in the launch of Kerendia (finerenone) by Bayer, a German pharmaceutical and biotech entity in February 2022, in India. Recommended for patients with type two diabetes and chronic renal disease, finerenone is the first of its kind, non-steroidal, and a selective antagonist of the mineralocorticoid receptor. Its mechanism involves inhibiting the overactivation of the mineralocorticoid receptor (MR), widely considered a contributing element to chronic kidney disease (CKD) and cardiovascular damage development.

What Are the Main Segments in the Late Stage Chronic Kidney Disease Drugs Market?
The late stage chronic kidney disease drugs market covered in this report is segmented -

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12196&type=smp

Which Top Companies are Driving Growth in the Late Stage Chronic Kidney Disease Drugs Market?
Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc

Which Regions Will Dominate the Late Stage Chronic Kidney Disease Drugs Market Through 2029?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12196

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.